Literature DB >> 11082474

Birth outcomes following prenatal exposure to fluoxetine.

L S Cohen1, V L Heller, J W Bailey, L Grush, J S Ablon, S M Bouffard.   

Abstract

BACKGROUND: Although pregnancy has frequently been described as a time of emotional well-being, some women experience significant antenatal depression that may require treatment with antidepressants. The purpose of this investigation was to examine the relative effects of early and late trimester exposure to fluoxetine and perinatal outcome.
METHODS: Obstetric and neonatal records were reviewed for 64 mother-infant pairs where there was documented use of fluoxetine at some point during pregnancy. Differences in several measures of obstetrical outcome and neonatal well-being were examined in early trimester- and late trimester-exposed infants.
RESULTS: No differences in birth weight and acute neonatal outcome were evident across the two groups, though there was a higher frequency of special care nursery admissions for infants with exposure to fluoxetine late in pregnancy. Special care nursery admissions could not be attributed to any specific factor.
CONCLUSIONS: Given the growing numbers of women who are treated with antidepressants, including fluoxetine, during pregnancy, and the strong association between depression during pregnancy and risk for postpartum depression, patients may be best advised to continue treatment with antidepressants through labor and delivery versus making any change in intensity of treatment during the acute peripartum period.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11082474     DOI: 10.1016/s0006-3223(00)00877-5

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  28 in total

Review 1.  Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy: a focus on methodological issues.

Authors:  Luke E Grzeskowiak; Andrew L Gilbert; Janna L Morrison
Journal:  Drug Saf       Date:  2011-11-01       Impact factor: 5.606

Review 2.  Fetal effects of psychoactive drugs.

Authors:  Amy L Salisbury; Kathryn L Ponder; James F Padbury; Barry M Lester
Journal:  Clin Perinatol       Date:  2009-09       Impact factor: 3.430

Review 3.  Prenatal antidepressant exposure: clinical and preclinical findings.

Authors:  Chase H Bourke; Zachary N Stowe; Michael J Owens
Journal:  Pharmacol Rev       Date:  2014-02-24       Impact factor: 25.468

Review 4.  Antidepressant use in pregnancy: a critical review focused on risks and controversies.

Authors:  N Byatt; K M Deligiannidis; M P Freeman
Journal:  Acta Psychiatr Scand       Date:  2012-12-14       Impact factor: 6.392

Review 5.  Treating mood disorders during pregnancy: safety considerations.

Authors:  Malin Eberhard-Gran; Anne Eskild; Stein Opjordsmoen
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 6.  Antidepressant use in pregnant and postpartum women.

Authors:  Kimberly A Yonkers; Katherine A Blackwell; Janis Glover; Ariadna Forray
Journal:  Annu Rev Clin Psychol       Date:  2013-12-02       Impact factor: 18.561

7.  Air pollution exposure during critical time periods in gestation and alterations in cord blood lymphocyte distribution: a cohort of livebirths.

Authors:  Caroline E W Herr; Miroslav Dostal; Rakesh Ghosh; Paul Ashwood; Michael Lipsett; Kent E Pinkerton; Radim Sram; Irva Hertz-Picciotto
Journal:  Environ Health       Date:  2010-08-02       Impact factor: 5.984

Review 8.  Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy: A Review of Current Evidence.

Authors:  Sura Alwan; Jan M Friedman; Christina Chambers
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

Review 9.  Perinatal depression: treatment options and dilemmas.

Authors:  Teri Pearlstein
Journal:  J Psychiatry Neurosci       Date:  2008-07       Impact factor: 6.186

10.  Maternal depression and medication exposure during pregnancy: comparison of maternal retrospective recall to prospective documentation.

Authors:  D J Newport; P A Brennan; P Green; D Ilardi; T H Whitfield; N Morris; B T Knight; Z N Stowe
Journal:  BJOG       Date:  2008-05       Impact factor: 6.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.